Simultaneous determination of rivaroxaban and sitagliptin in rat plasma by LC-MS/MS and its application to pharmacokinetic drug-drug interaction study

3Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

A sensitive and accurate LC-MS/MS method was developed and validated for the simultaneous quantification of rivaroxaban (RIV) and sitagliptin (SIT) in rat plasma using apixaban as internal standard (IS). An Agilent Eclipse plus C18 column (2.1 × 100 mm, 3.5 μm, Agilent) was used for chromatographic separation with isocratic elution. Multiple reaction monitoring (MRM) using positive-ion ESI mode to monitor ion transitions of m/z 436.8→144.9 for RIV, m/z 407.7→173.8 for SIT, m/z 459.8→442.8 for IS. The procedure of method validation included selectivity, linearity, precision, accuracy, matrix effect, extraction recovery and stability were conducted according to the guidelines of EMA and FDA. The results indicated that no obvious drug-drug interactions occurred might be owing to their differences in metabolic pathways.

Cite

CITATION STYLE

APA

Wang, L., Shang, K., Zhang, X., Zhang, X., Feng, T., Xu, X., & Wang, F. (2022). Simultaneous determination of rivaroxaban and sitagliptin in rat plasma by LC-MS/MS and its application to pharmacokinetic drug-drug interaction study. Acta Chromatographica, 34(4), 430–436. https://doi.org/10.1556/1326.2021.00988

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free